吉西他滨联合顺铂术前新辅助化疗对肺鳞癌患者疗效及鳞状细胞癌相关抗原、胃泌素释放肽前体水平的影响

Effects of Preoperative Neoadjuvant Chemotherapy of Gemcitabine Combined with Cisplatin on the Efficacy and SCC,ProGRP Level of Patients with Lung Squamous Cell Carcinoma

目的探讨吉西他滨联合顺铂术前新辅助化疗对肺鳞癌患者疗效及鳞状细胞癌相关抗原(SCC)、胃泌素释放肽前体(Pro GRP)水平的影响。方法选取2018年3月至2020年6月在朝阳市第二医院接受治疗的200例肺鳞癌患者作为研究对象,按随机数字表法分为观察组与对照组,各100例。观察组给予吉西他滨以及顺铂的新辅助化疗,对照组给予重酒石酸长春瑞滨注射液及顺铂的新辅助化疗。比较两组疗效,治疗前及治疗后SCC、Pro GRP水平,以及两组不良反应。结果观察组治疗有效率是47.00%,明显高于对照组的33.00%(P<0.05)。治疗后,两组SCC、Pro GRP水平明显低于治疗前,且观察组明显低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率与对照组比较差异无统计学意义(P>0.05)。结论吉西他滨与顺铂联合进行术前新辅助化疗对肺鳞癌患者的疗效较好,还可有效改善SCC、Pro GRP水平,安全性也较高。

Objective To investigate the effect of preoperative neoadjuvant chemotherapy of gemcitabine combined with cisplatin on the efficacy and SCC,ProGRP level of patients with lung squamous cell carcinoma.Methods A total of 200 patients with lung squamous cell carcinoma treated in Chaoyang Second Hospital from March 2018 to June 2020 were selected as observation objects.According to the random number table method,the patients were divided into observation group and control group,each with 100 cases.Neoadjuvant chemotherapy of gemcitabine and cisplatin was given in the observation group,the control group was given neoadjuvant chemotherapy with vinorelbine bitartrate injection and cisplatin.The efficacy,SCC,ProGRP levels before and after treatment,and adverse reactions of the 2 groups were compared.Results The total treatment effective rate of observation group was 47.00%,compared with the control group of 33.00%was significantly higher(P<0.05).After treatment,both groups had significantly lower SCC,ProGRP levels than before treatment,and the observation group was obviously lower than the control group,the difference was statistically significant(P<0.05).Compared with the control group,the incidence of adverse reactions in the observation group was not statistically significant(P>0.05).Conclusion The preoperative neoadjuvant chemotherapy of gemcitabine combined with cisplatin has a better efficacy in patients with lung squamous cell carcinoma,which can also effectively improve the level of SCC,ProGRP,and has high safety.